REDUCE-AMI
2024
Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction
In 5,020 patients after acute MI with preserved LVEF (≥50%), beta-blocker therapy did not reduce all-cause death or new MI compared with no beta-blocker.
Result
Efficacy: Death from any cause or new myocardial infarctionHR 0.96 (95% CI 0.79-1.16) · P = 0.64
Below 1 favours beta-blocker therapy, above 1 favours no beta-blocker.
- Absolute difference
- 0.4 points
The absolute difference is derived from the event rates.
Also reported: Neutral over median ~3.5 years in post-MI patients with LVEF ≥50%.
- Subtopic
- beta-blocker
- Design
- Registry-based open-label RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ACC/AHA 2025 ACS
- Source
- Yndigegn T, et al. N Engl J Med. 2024;390(15):1372-81.doi 10.1056/NEJMoa2401479
Discussion & critique
Open-label with lower-than-expected event rates in a well-revascularised population. First modern RCT to challenge routine beta-blockade after MI with preserved EF and, with REBOOT, shifting guidelines.